# Clinical Evaluation of a Patient with a Dysfunctional Prosthetic Aortic Valve Before Pregnancy A True Clinical Challenge

#### Rafael Kuperstein MD

Pregnancy with Heart Disease Service

The Leviev Heart Center

Sheba Medical Center

Israel





### **The Patient**

- 39 years old woman G0P0
- 2012: Syncope due to previously unknown severe aortic stenosis
- 2012: Biological AVR (Magna Ease 19 mm)
- 02/15: Referred from another hospital for re-do AVR due to ↑ gradients across the prosthetic valve in order to allow a future pregnancy
- Pre-operative evaluation requested by cardiac surgeons





### **The Patient**

- Currently asymptomatic
- No co-morbidities
- First post operative echo(2012): AV Δ 34/21 mmHg
- Last echo(exercise stress echo in 2014): Normal LV size, no LVH, LVEF=65%
- Resting Δ 68/35 mmHg, walked 6 and a half
   minutes Δ ↑ to 115/86 mmHg, SPAP: 56 mmHg
- No symptoms





## **Objectives**

- Define aortic stenosis severity
- Echocardiographic evaluation of Aortic Stenosis
- Pitfalls on severity evaluation
- Assessment of prosthetic Valves
- Surgical indications
- Aortic stenosis in pregnancy

## Aortic Stenosis: Classification

	Sclerosis	Mild	Moderate	Severe	
Jet Velocity(m/sec)	<2.5	2.6-2.9	3.0-4.0	>4.0	
Mean Gradient (mmHg)		<20	20-40	>40	
Valve Area (cm²)		>1.5	1.0-1.5	<1.0	
Valve Area Index(cm²/m²)		>0.85	0.6-0.85	<0.6	

**ESC** and **ACC**-Guidelines





## Echocardiographic Evaluation of Aortic Stenosis The Continuity Equation


 Continuity equation states that the stroke volume ejected through the LVOT all passes through the stenotic AV

AVA=CSA<sub>LVOT</sub> x VTI<sub>LVOT</sub>/VTI<sub>AV</sub>

Calculation of continuity equation valve area requires 3

measurements


- AS velocity by CW
- LVOT diameter
- LVOT velocity by PW





## Comparing Pressure Gradients Calculated from Doppler Velocities to Pressures Measured at Cardiac Catheterization

- Peak to peak Δ
- Peak instantaneous Δ






## Pitfalls on the Assessment of Severity

## Sources of error for pressure gradient calculations

 Pressure Recovery is greatest in patients with narrow aortas (<3 cm diameter)</li>





## **Evaluation of the Prosthetic Aortic Valve**


#### **Imaging Considerations**

- Identify the sewing ring and surrounding area
- Leaflets of normal tissue valves should be thin with an unrestricted motion

## **Evaluation of the Prosthetic Aortic Valve**

### **Doppler Considerations**

- Doppler velocity
- Wave shape
- Velocity ratio





## **Doppler & Prosthetic AV**

- High gradients may be seen with normal functioning valves with:
  - Small size
  - Increased stroke volume
  - Patient prosthetic mismatch(PPM)
  - Valve obstruction
- Thus, the ability to distinguish malfunctioning from normal PVs in high flow states on the basis of gradients alone may be difficult

## Prosthetic Valve Evaluation

#### Magna Ease 19 mm

- Expected gradients
  - Peak: 32 ± 3.4 mmHg
  - Mean: 24.8 ± 8.6 mmHg
  - Expected EOA: 1.2±0.3 cm²






### **Our Patient Re-Evaluation**

- Normal LV size, No LVH, LVEF=65%
- Peak  $\Delta = 53/31$ mmHg, EOA=0.69 cm<sup>2</sup>,
- LVOT Diameter= 1.7 cm,
- Asc Ao Diameter= 2.4 cm
- Pressure Recovery was calculated
- PR=14mmHg
- Net gradient (53-14) = 39 mmHg
- AVA corrected for PR=0.82 cm<sup>2</sup>
- Acceleration time: 90 ms
- DVI ratio=0.3





## **Our Patient Re-Evaluation**



## **Additional Investigations**

#### **Exercise Stress Echo**


6'30" Bruce protocol, Maximal Δ=81/55 mmHg,
 Maximal SPAP 55 mmHg. No symptoms

#### TEE


- Mildly thickened leaflets with normal motion
- Anatomic AVA: 0.9 cm<sup>2</sup>
- Cardio-pulmonary exercise test: normal

#### Prognostic Value of Exercise-Stress Echocardiography in Asymptomatic Patients With Aortic Valve Stenosis


#### Rest Mean A



#### Exercise Mean Δ Increase



#### SPAP at Peak Exercise



n=148

On multivariable analysis only Mean  $\Delta$  at rest predicted long term outcomes

Goublaire, J Am Coll Img 2018





## **Surgical Indications**

C) Asymptomatic patients with severe aortic stenosis (refers only to patients eligible for surgical valve replacement)					
SAVR is indicated in asymptomatic patients with severe aortic stenosis and systolic LV dysfunction (LVEF <50%) not due to another cause.	1	С			
SAVR is indicated in asymptomatic patients with severe aortic stenosis and an abnormal exercise test showing symptoms on exercise clearly related to aortic stenosis.	1	С			
SAVR should be considered in asymptomatic patients with severe aortic stenosis and an abnormal exercise test showing a decrease in blood pressure below baseline.	Ha	С			
SAVR should be considered in asymptomatic patients with normal ejection fraction and none of the above-mentioned exercise test abnormalities if the surgical risk is low and one of the following findings is present:  • Very severe aortic stenosis defined by a V <sub>max</sub> >5.5 m/s  • Severe valve calcification and a rate of V <sub>max</sub> progression ≥0.3 m/s/year  • Markedly elevated BNP levels (>threefold age- and sex-corrected normal range) confirmed by repeated measurements without other explanations  • Severe pulmonary hypertension (systolic pulmonary artery pressure at rest >60 mmHg confirmed by invasive measurement) without other explanation.	Ha	n			

ESC Valvular Guidelines 2017





## **Surgical Indications**

Recommendations for Prosthetic Valve Stenosis						
COR	LOE	Recommendations				
I	C	Repeat valve replacement is indicated for severe symptomatic prosthetic valve stenosis (239-241).				

AHA/ACC Updated Valvular Guidelines, 2017



## And what About Pregnancy with Aortic Stenosis



## Guidelines

#### Class IIa

1. Exercise testing is reasonable in asymptomatic patients with severe AS (aortic velocity ≥4.0 m per second or mean pressure gradient ≥40 mm Hg, stage C) before pregnancy. (Level of Evidence: C)

#### Class I

- 4. Pregnant patients with severe valve stenosis (stages C and D) should be monitored in a tertiary care center with a dedicated Heart Valve Team of cardiologists, surgeons, anesthesiologists, and obstetricians with expertise in the management of high-risk cardiac patients during pregnancy. (Level of Evidence: C)
- \* Pregnancy should be discouraged in women with severe symptomatic aortic stenosis

\* ESC Valvular Guidelines 2017







From the Multinational ROPAC Registry

- 96 women with moderate or severe AS
- Severe AS(n=34): Peak Δ ≥ 64 mmHg
- Moderate AS (n=62): Peak Δ ≥ 36 mmHg
  - 7 patients had an Aortic Bioprosthesis
  - (Peak  $\triangle$  47±6.5 mmHg, mean  $\triangle$  28±5.5 mmHg)





From the Multinational ROPAC Registry

TABLE 1 Maternal Baseline Char	acteristics						
	All AS Patients	Moderate AS	Severe AS	p Value	Asymptomatic Patients	Symptomatic Patients	p Value
Number of patients	96	62	34		60	36	
Age in yrs	30.3 (26.0-32.8)	29.8 (26.3-32.9)	30.6 (25.9-32.7)	0.96	30.5 (26.2-33.4)	29.9 (25.8-32.8)	0.67
Nulliparous	47 (49)	36 (58.1)	11 (32.4)	0.028	36 (60)	11 (30.6)	0.01
Prior cardiac intervention	48 (50)	34 (54.8)	14 (41.2)	0.11	30 (50.0)	18 (50)	0.83
NYHA functional class							
l I	60 (62.5)	45 (72.6)	15 (44.1)	0.02	60 (100)	-	-
П	32 (33.3)	15 (24.2)	17 (50.0)		-	32 (88.9)	
Ш	4 (4.2)	2 (3.2)	2 (5.9)		-	4 (11.1)	
IV	0 (0)	0 (0)	0 (0)		-	0 (0)	
AS location							
Valvular	59 (61.5)	45 (72.6)	18 (52.9)	0.02	35 (58.3)	24 (66.7)	0.49
Subvalvular	22 (22.9)	11 (17.7)	11 (32.4)		16 (26.7)	6 (16.7)	
Supravalvular	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	
Not specified	15 (15.6)	10 (16.1)	5 (14.7)		9 (15.0)	6 (16.7)	
Bicuspid aortic valve	46 (53.5)	34 (60.7)	12 (40.0)	0.18	35 (64.8)	11 (34.4)	0.02
Peak aortic gradient, mm Hg	62.1 ± 26.3	$47.5 \pm 6.9$	$88.7 \pm 28.0$	<0.0001	$56.8 \pm 20.1$	71.1 ± 32.7	0.006
Mean aortic gradient, mm Hg	$\textbf{39.1} \pm \textbf{17.9}$	$27.8 \pm 5.3$	$55.1 \pm 17.4$	<0.0001	$\textbf{35.4}\pm\textbf{16.0}$	$44.3\pm19.5$	0.006
Left ventricular function	$65.6 \pm 8.7$	67.4 ± 6.2	62.4 ± 11.5	0.27	66.6 ± 7.1	64.0 ± 10.7	0.60







From the Multinational ROPAC Registry

- No maternal mortality
- 2 miscarriages
- 1 fetal death (woman severe AS and previous heart failure)







From the Multinational ROPAC Registry

#### **Maternal Outcomes**

	All AS Patients	Moderate AS	Severe AS	p Value	Asymptomatic Patients	Symptomatic Patients	p Value
Maternal mortality	0	-	-	-	-	-	-
Maternal hospital admission	34 (35.8)	17 (27.4)	17 (51.5)	0.027	21 (35.0)	13 (37.1)	0.42
Maternal cardiac hospital admission	20 (20.8)	8 (12.9)	12 (35.3)	0.02	9 (15.0)	11 (30.6)	0.12
Cardiac complications							
Heart failure	11 (11.5)	5 (8.1)	6 (17.6)	0.29	5 (8.3)	6 (16.7)	0.36
Arrhythmias (SVT)	1 (1.0)	1 (1.6)	0 (0)	0.76	1 (1.7)	0 (0)	0.80
Arrhythmias (VT/VF)	1 (1.0)	0 (0)	1 (2.9)	0.76	0 (0)	1 (2.8)	0.79
Endocarditis	1 (1.0)	1 (1.6)	0 (0)	0.76	1 (1.7)	0 (0)	0.80
Valve thrombosis	0 (0)	0 (0)	0 (0)	_	0 (0)	0 (0)	_
Cerebrovascular complication	0 (0)	0 (0)	0 (0)	_	0 (0)	0 (0)	_
Pulmonary embolism	0 (0)	0 (0)	0 (0)	_	0 (0)	0 (0)	_
Deep venous thrombosis	0 (0)	0 (0)	0 (0)	_	0 (0)	0 (0)	_
Obstetric complications							
Pregnancy-induced hypertension	3 (3.2)	2 (3.2)	1 (3.0)	0.57	2 (3.3)	1 (2.9)	0.63
(Pre-)eclampsia	3 (3.2)	3 (4.8)	0 (0)	0.50	3 (5.0)	0 (0)	0.46
Cesarean section	54 (57.4)	30 (48.3)	24 (75.0)	0.008	30 (50.0)	24 (70.6)	0.029
Hemorrhagic events	4 (4.2)	4 (6.5)	0 (0)	0.33	4 (66.7)	0 (0)	0.29







From the Multinational ROPAC Registry

#### **Fetal Outcomes**

	All AS Patients	Moderate AS	Severe AS	p Value	Asymptomatic Patients	Symptomatic Patients	p Value
Fetal outcome							
Apgar score <7	8 (9.0)	3 (5.2)	5 (16.1)	0.21	4 (7.0)	4 (12.5)	0.37
Pregnancy duration (weeks)	$\textbf{37.2}\pm\textbf{5.2}$	$\textbf{38.0} \pm \textbf{4.4}$	$\textbf{35.5} \pm \textbf{6.4}$	0.002	$37.0\pm6.2$	$37.5\pm2.8$	0.08
Pre-term birth <37 weeks	18 (20.9)	8 (16.0)	10 (35.7)	0.017	10 (18.2)	8 (25.8)	0.49
Mean birth weight, g	3,010 $\pm$ 691	$\textbf{3,198} \pm \textbf{549}$	$\textbf{2,648} \pm \textbf{797}$	0.003	$\textbf{3,091} \pm \textbf{642}$	$\textbf{2,878} \pm \textbf{758}$	0.24
Low birth weight (<2,500 g)	16 (16.2)	4 (6.0)	12 (35.0)	0.006	6 (10.0)	10 (27.8)	0.037
Small for gestational age	8 (9.3)	2 (3.4)	6 (21.4)	0.022	3 (5.5)	5 (16.1)	0.21
Miscarriages	2 (2.1)	2 (3.2)	0 (0)	0.76	2 (3.3)	0 (0)	0.71
Fetal death	0 (0)	0 (0)	0 (0)	_	0 (0)	0 (0)	-
Neonatal death	1 (1.1)	0 (0)	1 (3.3)	0.05	0 (0)	1 (3.0)	0.38







From the Multinational ROPAC Registry


- On Mutivariable Analysis
  - Only peak Δ predicted maternal outcomes
  - Peak Δ and AS severity predicted fetal outcomes







From the Multinational ROPAC Registry





## **Back to Our Patient**

- Surgery was cancelled
- Asymptomatic (2016-2017)
- No further changes on gradients or functional capacity
- BNP: Normal
- Request for IVF with egg donation accepted

### **Back to Our Patient**

- 08/17: Pregnant
- Asymptomatic during all pregnancy
- Baseline BNP and at 32 weeks were normal
- LVEF个 to 75%, AV gradients 个 to 103/55 mmHg (week 32)
- Delivered on week 36+4: Elective Cesarean
- Apgar 9/10, 2560 g
- Aortic Δ before discharge: 57/32 mmHg
- Discharged home on POD 7



## Thank You!!!



